国家医保局：推动创新药积极进医院 完善医保支付标准

Core Viewpoint - The National Healthcare Security Administration (NHSA) has introduced measures to support the high-quality development of innovative drugs, emphasizing the need for improved management and clinical use of these drugs in healthcare institutions [1][2]. Group 1: Support for Innovative Drugs - The NHSA encourages healthcare institutions to actively incorporate innovative drugs into their practices, allowing for flexibility in drug procurement without being limited by existing drug directories or ratios [1]. - In 2022, the evaluation of drug varieties and specifications in tertiary hospitals was adjusted, removing previous restrictions at the national level [1]. Group 2: Enhancing Clinical Use Capabilities - There is a focus on improving the clinical use capabilities of innovative drugs, with an emphasis on guiding healthcare professionals to use these drugs safely and effectively [2]. - The NHSA encourages industry associations and healthcare institutions to summarize experiences in the use of innovative drugs to enhance their application [2]. Group 3: Optimizing Reimbursement Standards - The NHSA aims to refine the reimbursement standards for innovative drugs, allowing healthcare institutions to apply for special cases if the drugs do not fit into the standard payment categories [2]. - The NHSA is also working on reforming the settlement process and implementing a prepayment system for medical insurance funds, which has shown positive effects on fund efficiency and cash flow for healthcare institutions [2].